[ad_1]
On Day 3, the Korean Centers for Disease Control and Prevention (KCDC) reported on Day 3 that they had completed a vaccine purchase contract with AstraZeneca, saying: “It is not an official government position. The government is currently negotiating with individual companies for the introduction of the Corona 19 vaccine. ” I can’t reveal the details. ” [사진=로이터 연합뉴스]
Regarding media reports that the government signed a contract with AstraZeneca, a vaccine developer for Corona 19 (a novel coronavirus infection), he took a cautious position and said: “Negotiations with individual companies are ongoing.” . While negotiations with several companies are still ongoing, the report expressed concern that such a report on the existence of a contract could affect other contracts.
On the 3rd, the Korea Centers for Disease Control and Prevention said, “It is not an official government position,” in connection with the report that the Agency for Disease Control and Prevention has completed a contract of purchase vaccines with AstraZeneca. I cannot reveal the details. “
The vaccine, which AstraZeneca is developing in conjunction with the University of Oxford in the UK, was announced last month to have an average effectiveness of 70% in the Phase 3 mid-term evaluation.
It is lower than Pfizer (95%) or Modena (94.5%), but the price is as low as $ 4 (4,390 won for 3 days) and unlike Pfizer (minus 70 degrees) and Modena (minus 20 degrees), the general refrigeration temperature (It is also considered an advantage that it can be stored for at least half a year at 2 ~ 8 degrees). In particular, it is being produced on consignment in Korea, so the possibility of domestic introduction is envisaged.
Some have even said they have signed a vaccine supply contract, but the government is in a position to reveal the details of the negotiations when all related negotiations are completed. It is difficult to know whether the final contract will be made until the official announcement, and in a situation where several companies are being negotiated on various vaccines, it is judged that there is no advantage in the negotiations if the contract with some pharmaceutical companies is known.
The government has negotiated purchase contracts for 5 corona vaccine products19 that have entered phase 3 clinical trials.
AstraZeneca, whose contract was first signed, is reported to have been negotiating with Pfizer, which approved emergency use in the UK on the 2nd, with Johnson & Johnson, Modena and NovaVax.
The government initially planned to insure 10 million people through the COVAX facility, an international project for the joint purchase and distribution of vaccines, and to purchase an additional 20 million people through individual negotiations with global pharmaceutical companies. More than 30 million people are expected to be able to secure the supply.
Health and Welfare Minister Park Neung-hoo recently said: “We are looking for considerably more contracts than 30 million people, which is 60% of the total population.” In next year’s budget, 900 billion won has been allocated to purchase vaccines to increase the number of vaccination targets to 44 million.
Reporter Kang Kyung-joo [email protected]
Ⓒ Hankyung.com prohibits unauthorized reproduction and redistribution
